ITA3404
ITA3404
ITA3404
from
$526.00
Price in reward points: 526
- Catalog: ITA3404
- Gene/Protein: BCL11B
- Product Description: Immunotag™ BCL11B Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein BCL11B Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC,ELISA Recommended Dilution WB 1:500-1:2000 IHC 1:50-1:200 Concentration 1 mg/ml Reactive Species Human,Rat Host Species Rabbit Immunogen A synthesized peptide Specificity BCL11B antibody detects endogenous levels of total BCL11B Purification The antiserum was purified by peptide affinity chromatography. Form Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Gene Name BCL11B Accession No. Q9C0K0 Alternate Names ATL1 alpha; ATL1; ATL1 beta; ATL1 gamma; ATL1-delta; B cell CLL/lymphoma 11B/T cell receptor delta constant region fusion protein; B cell lymphoma/leukemia 11B; B-cell CLL/lymphoma 11B (zinc finger protein); B-cell CLL/lymphoma 11B; B-cell lymphoma/leukemia 11B; BC11B_HUMAN; BCL-11B; Bcl11b; BCL11B/TRDC fusion; COUP TF interacting protein 2; COUP-TF interacting protein 2; COUP-TF-interacting protein 2; Ctip 2; CTIP-2; CTIP2; hRIT1 alpha; hRit1; Radiation induced tumor suppressor gene 1; Radiation induced tumor suppressor gene 1 protein; Radiation-induced tumor suppressor gene 1 protein; Rit 1; Rit1; zinc finger protein hRit1 alpha; ZNF856B; Description Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of hematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus (PubMed:27959755). Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4+ T-lymphocytes (PubMed:16809611). Tumor-suppressor that represses transcription through direct, TFCOUP2-independent binding to a GC-rich response element (By similarity). May also function in the P53-signaling pathway (By similarity). Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 95 kDa Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | BCL11B |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,ELISA |
| Recommended Dilution | WB 1:500-1:2000 IHC 1:50-1:200 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Rat |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide |
| Specificity | BCL11B antibody detects endogenous levels of total BCL11B |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Gene Name | BCL11B |
| Accession No. | Q9C0K0 |
| Alternate Names | ATL1 alpha; ATL1; ATL1 beta; ATL1 gamma; ATL1-delta; B cell CLL/lymphoma 11B/T cell receptor delta constant region fusion protein; B cell lymphoma/leukemia 11B; B-cell CLL/lymphoma 11B (zinc finger protein); B-cell CLL/lymphoma 11B; B-cell lymphoma/leukemia 11B; BC11B_HUMAN; BCL-11B; Bcl11b; BCL11B/TRDC fusion; COUP TF interacting protein 2; COUP-TF interacting protein 2; COUP-TF-interacting protein 2; Ctip 2; CTIP-2; CTIP2; hRIT1 alpha; hRit1; Radiation induced tumor suppressor gene 1; Radiation induced tumor suppressor gene 1 protein; Radiation-induced tumor suppressor gene 1 protein; Rit 1; Rit1; zinc finger protein hRit1 alpha; ZNF856B; |
| Description | Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of hematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus (PubMed:27959755). Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4+ T-lymphocytes (PubMed:16809611). Tumor-suppressor that represses transcription through direct, TFCOUP2-independent binding to a GC-rich response element (By similarity). May also function in the P53-signaling pathway (By similarity). |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 95 kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |